Literature DB >> 18637966

Haemophilia care in China: achievements of a decade of World Federation of Hemophilia treatment centre twinning activities.

M-C Poon1, K-H Luke.   

Abstract

The World Federation of Hemophilia (WFH) began its involvement in China in 1993, supporting Chinese haemophilia centre twinning programmes in 1997. Although only three Chinese centres were in a twinning relationship (Tianjin/Calgary 1997-2004, Guangzhou/Ottawa 2000-2006, Shanghai/Ottawa, Calgary 2002-2007), WFH helped establish a collaborative network of six Chinese centres (Tianjin, Guangzhou, Shanghai, Beijing, Hefei, Jinan) in 2004. These network centres, in collaboration with haemophilia patients, shared and coordinated several successful ongoing priority projects (Registry, Nursing, Laboratory Diagnosis, Physiotherapy and Prophylaxis). A number of physicians, nurses and technologists have received WFH fellowships for training internationally. They are becoming haemophilia-care leaders and are key personnel working towards comprehensive care in China. National and regional workshops/conferences in addition to educational material development have been successful in reaching out to healthcare professionals and persons with haemophilia across the country. Key elements of success include the enthusiasm and commitment of the Chinese professionals and patient leaders in their desire to advance haemophilia care and their commitment to work collaboratively in a coordinated manner. They are beginning to gain national and international recognition and are launching outreach education and care programmes to cover other parts of China. WFH is now transitioning support in China from a twinning program to country programme (Global Alliance for Progress). Haemophilia work in China is still in the beginning, but there is now a solid foundation for future progress.

Entities:  

Mesh:

Year:  2008        PMID: 18637966     DOI: 10.1111/j.1365-2516.2008.01821.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  10 in total

1.  Recombinant factor VIII in the management of hemophilia A: current use and future promise.

Authors:  Jerry S Powell
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

2.  Retrospective analysis of 1,226 Chinese patients with haemophilia in a single medical centre.

Authors:  Min Xuan; Feng Xue; Rongfeng Fu; Yanhui Yang; Lei Zhang; Mengsu Tian; Renchi Yang
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

3.  Cross-cultural adaptation of the CHO-KLAT for boys with hemophilia in rural and urban China.

Authors:  Runhui Wu; Jishui Zhang; Koon Hung Luke; Xinyi Wu; Tricia Burke; Ling Tang; Man-Chiu Poon; Xiaojing Li; Min Zhou; Jing Sun; Marrisa Hang; Victor Blanchette; Nancy L Young
Journal:  Health Qual Life Outcomes       Date:  2012-09-15       Impact factor: 3.186

4.  Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial.

Authors:  Runhui Wu; Jing Sun; Weiqun Xu; Qun Hu; Wenqian Li; Jianwen Xiao; Feng'e Yang; Xiaojing Zeng; Yun Zeng; Jianfeng Zhou; Irina Matytsina; Sali Zhang; Michael Pluta; Renchi Yang
Journal:  Ther Clin Risk Manag       Date:  2020-06-23       Impact factor: 2.423

5.  Medical expenditure for patients with hemophilia in urban China: data from medical insurance information system from 2013 to 2015.

Authors:  Guang-Wen Gong; Ying-Chun Chen; Peng-Qian Fang; Rui Min
Journal:  Orphanet J Rare Dis       Date:  2020-06-05       Impact factor: 4.123

6.  Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial.

Authors:  Renchi Yang; Jing Sun; Yongqiang Zhao; Xuefeng Wang; Depei Wu; Despina Tseneklidou-Stoeter; Junde Wu; Nikki Church
Journal:  Haemophilia       Date:  2019-04-17       Impact factor: 4.287

Review 7.  The existing scenario of haemophilia care in Canada and China - A review.

Authors:  Rohan Pratap; Monali Misra; Varun N; Suman Morampudi; Anand Patil; Jayachandra Reddy
Journal:  Hematol Transfus Cell Ther       Date:  2019-10-27

8.  Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies.

Authors:  Renchi Yang; Yongqiang Zhao; Xuefeng Wang; Jing Sun; Runhui Wu; Chenghao Jin; Jie Jin; Depei Wu; Pablo Rendo; Feifei Sun; Jeremy Rupon; Francois Huard; Joan M Korth-Bradley; Lihong Xu; Binyu Luo; Yingxue Cathy Liu
Journal:  J Blood Med       Date:  2020-11-25

9.  Analysis of hospitalization of people with hemophilia-12 years of experience in a single center.

Authors:  Cuiyun Qu; Wei Liu; Lingling Chen; Lei Zhang; Feng Xue; Renchi Yang
Journal:  Res Pract Thromb Haemost       Date:  2022-07-21

10.  Health-related quality of life of patients with haemophilia: a cross-sectional survey in the Northeast of China.

Authors:  Jinyu Niu; Liangwen Ning; Qiao Zhang; Ze Liu; Yi Ma; Xiaoxue Xu; Qunhong Wu; Yanhua Hao; Yu Cui; Chaojie Liu
Journal:  BMJ Open       Date:  2022-02-01       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.